- The traditional BioCamp event is held in Bled, aimed at connecting students of science, technology and entrepreneurship with renowned experts and leading managers.
- This year, 35 students of nine nationalities at the three-day Novartis forum in Slovenia discuss advanced approaches in cancer treatment with the help of cutting-edge science and next-generation technologies.
- With the event, Novartis in Slovenia confirms its commitment to innovation, the development of young talents and the integration of the economic and academic spheres.
Bled, September 11, 2023 – For the 13th year in a row, the traditional scientific event BioCamp, organized by Novartis in Slovenia, provides young people from the region and beyond with an insight into the pharmaceutical industry and networking with renowned experts and leading managers. The theme of this year's event, in which 35 students of nine nationalities are participating, is "Reimagining Cancer Therapy – Cutting-edge science meets next generation technologies”.
"We are happy that, after several years of online implementation of the event, we are once again hosting the most promising students from the region and beyond. With this unique event, we present to young people the challenges and opportunities offered by the world of research and the international business environment of the innovative pharmaceutical industry. We believe that innovative, curious and agile talents are key to successful business and fulfilling our mission. BioCamp is one of our innovative HR practices, which for 13 years has offered young people an insight into current challenges in pharma industry and healthcare and the values of Novartis in Slovenia," said Dr. Ljerka Lah, Chair of the Organizing Committee of the BioCamp 2023, and added that more than 100 received applications for the event confirm the still great interest of young prospective experts in events that offer the opportunity to connect with established experts from various fields of activity.
Cutting-edge science and next-generation technologies to fight cancer
During the three-day forum, young people learn about the opportunities offered by digitization, automation and artificial intelligence in the fight against cancer, which is one of the leading causes of death in Slovenia and around the world. "With technologically sophisticated and advanced knowledge in the field of research and development and new approaches, we want to alleviate the biggest burdens of disease in modern society, which is why oncology is one of the key therapeutic areas of Novartis. At this year's BioCamp, we present to young people how, using advanced approaches, we are looking for innovative solutions for patients all over the world," said Prof. Dr. Uroš Urleb, director of Novartis d.o.o. and Executive Director of Scientific Office in TRD Biologics & CGT at Novartis.
BioCamp opens the door to the world of innovative pharmaceutical industry
BioCamp offers perspective students of science, technology and entrepreneurship an invaluable opportunity to network with top experts from Slovenia and abroad as well as other young talents. "Connecting the economic and academic spheres with the aim of finding breakthrough solutions for the biggest challenges in the pharmaceutical industry and healthcare is one of the key partnerships we are building at Novartis in Slovenia. That's why we encourage young talents at BioCamp to, in addition to gathering knowledge at lectures and workshops, also find a solution to a real challenge and present it to the expert committee. In this way, they show us their knowledge and way of thinking and open up many career opportunities," added Dr. Ljerka Lah.
This year's BioCamp takes place from September 10 to 12, 2023 in Bled. With the event, Novartis in Slovenia has connected more than 500 young talents in thirteen years, of which more than 50 have been employed in Novartis to date.
* * *
About Novartis
Novartis is reimagining medicine to improve and extend people’s lives. We deliver high-value medicines that alleviate society’s greatest disease burdens through technology leadership in R&D and novel access approaches. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. About 103,000 people of more than 140 nationalities work together to bring Novartis products to nearly 800 million people around the world. Find out more at https://www.novartis.com
* * *
This press release contains statements and forecasts of future business operations. The forecasts include estimates based on all the information currently available to us. Should these forecasts prove unreliable, the actual results of business operations could be different from those expected.
- end -
For further information, please contact:
Mateja Breznik
Communication & Engagement
Novartis LLC